LT3536324T - 4-okso-3,4-dihidro-1,2,3-benzotriazinai, kaip gpr139 moduliatoriai - Google Patents

4-okso-3,4-dihidro-1,2,3-benzotriazinai, kaip gpr139 moduliatoriai

Info

Publication number: LT3536324T
Authority: LT; Lithuania
Prior art keywords: gpr139; benzotriazines; modulators; dihydro; oxo
Prior art date: 2014-11-20

Application number

LTEP19152036.0T

Other languages

English (en)

Inventor

Stephan HITCHCOCK

Betty Lam

Holger Monenschein

Holly REICHARD

Original Assignee

Takeda Pharmaceutical Company Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-20

Filing date

2015-11-19

Publication date

2021-12-10

2015-11-19 Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited

2021-12-10 Publication of LT3536324T publication Critical patent/LT3536324T/lt

Links

101000996780 Homo sapiens Probable G-protein coupled receptor 139 Proteins 0.000 title 1
102100033836 Probable G-protein coupled receptor 139 Human genes 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Addiction (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LTEP19152036.0T 2014-11-20 2015-11-19 4-okso-3,4-dihidro-1,2,3-benzotriazinai, kaip gpr139 moduliatoriai LT3536324T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462082539P	2014-11-20	2014-11-20
US201562184729P	2015-06-25	2015-06-25

Publications (1)

Publication Number	Publication Date
LT3536324T true LT3536324T (lt)	2021-12-10

Family

ID=55022667

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP15816275.0T LT3221298T (lt)	2014-11-20	2015-11-19	4-okso-3,4-dihidro-1,2,3-benzotriazino dariniai kaip gpr139 moduliatoriai
LTEP19152036.0T LT3536324T (lt)	2014-11-20	2015-11-19	4-okso-3,4-dihidro-1,2,3-benzotriazinai, kaip gpr139 moduliatoriai

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP15816275.0T LT3221298T (lt)	2014-11-20	2015-11-19	4-okso-3,4-dihidro-1,2,3-benzotriazino dariniai kaip gpr139 moduliatoriai

Country Status (40)

Country	Link
US (5)	US9556130B2 (lt)
EP (2)	EP3221298B1 (lt)
JP (2)	JP6637501B2 (lt)
KR (1)	KR102582021B1 (lt)
CN (2)	CN112062730B (lt)
AU (1)	AU2015349866B2 (lt)
CA (1)	CA2968242C (lt)
CL (1)	CL2017001292A1 (lt)
CO (1)	CO2017005959A2 (lt)
CR (1)	CR20170275A (lt)
CY (2)	CY1122613T1 (lt)
DK (2)	DK3221298T3 (lt)
DO (1)	DOP2017000120A (lt)
EA (1)	EA033728B1 (lt)
EC (1)	ECSP17038999A (lt)
ES (2)	ES2734735T3 (lt)
GE (2)	GEP20196961B (lt)
HR (2)	HRP20212009T1 (lt)
HU (2)	HUE057451T2 (lt)
IL (1)	IL252311B (lt)
JO (1)	JO3719B1 (lt)
LT (2)	LT3221298T (lt)
MA (1)	MA40993B1 (lt)
MD (1)	MD3221298T2 (lt)
MX (1)	MX378158B (lt)
MY (1)	MY187423A (lt)
NZ (1)	NZ732208A (lt)
PE (1)	PE20170899A1 (lt)
PH (1)	PH12017500920B1 (lt)
PL (2)	PL3536324T3 (lt)
PT (2)	PT3221298T (lt)
RS (2)	RS59078B1 (lt)
SG (1)	SG11201704002UA (lt)
SI (2)	SI3221298T1 (lt)
SM (2)	SMT201900355T1 (lt)
TN (1)	TN2017000196A1 (lt)
TW (1)	TWI684590B (lt)
UA (1)	UA120375C2 (lt)
UY (1)	UY36406A (lt)
WO (1)	WO2016081736A1 (lt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3719B1 (ar) *	2014-11-20	2021-01-31	Takeda Pharmaceuticals Co	4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
US12042496B2 (en)	2018-10-16	2024-07-23	The University Of Florida Research Foundation, Incorporated	Methods related to opioid therapeutics
WO2020097609A1 (en) *	2018-11-09	2020-05-14	Blackthorn Therapeutics, Inc.	Gpr139 receptor modulators
TWI873185B (zh) *	2019-09-16	2025-02-21	日商武田藥品工業股份有限公司	唑稠合之嗒-3(2h)-酮衍生物
WO2021127459A1 (en) *	2019-12-20	2021-06-24	Blackthorn Therapeutics, Inc.	Gpr139 receptor modulators
JP7697974B2 (ja) *	2020-05-08	2025-06-24	武田薬品工業株式会社	Ｇｐｒ１３９アゴニストの置換ベンゾトリアジノン代謝物
US20230310441A1 (en) *	2020-09-21	2023-10-05	Takeda Pharmaceutical Company	Treatment for schizophrenia
US11760788B2 (en)	2021-03-02	2023-09-19	Pathways Neuro Pharma, Inc.	Neuroreceptor compositions and methods of use
CN116693536A (zh) *	2022-03-01	2023-09-05	上海科技大学	吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
CN116693545A (zh) *	2022-03-01	2023-09-05	上海科技大学	噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
CN117986183A (zh) *	2022-10-28	2024-05-07	浙江友宁生物医药科技有限公司	一种gpr139受体激动剂、其制备方法及其应用
WO2024102802A1 (en) *	2022-11-11	2024-05-16	Takeda Pharmaceutical Company Limited	Zelatriazin for the treatment of depression
WO2025119351A1 (zh) *	2023-12-08	2025-06-12	深圳湾实验室	Gpr139激动剂
CN117815217B (zh) *	2023-12-29	2026-07-10	郑州大学第三附属医院(河南省妇幼保健院)	一种苯甲酰胺衍生物改善认知功能障碍的用途
WO2025162441A1 (zh) *	2024-02-02	2025-08-07	上海科技大学	稠杂环类化合物与其制备方法、药物组合物及应用
CN121159462A (zh) *	2025-11-19	2025-12-19	杭州市第七人民医院(杭州市心理危机研究与干预中心)	喹唑啉酮类化合物及其在制备神经系统疾病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3794726A (en) *	1972-08-21	1974-02-26	Uniroyal Inc	Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
EP0257102B1 (en)	1986-02-24	1997-11-19	Mitsui Petrochemical Industries, Ltd.	Agents for treating neurophathy
ATE108791T1 (de) *	1987-11-04	1994-08-15	Beecham Group Plc	Neue 4-oxobenzotriazine und 4-oxochinazoline.
CA2526506A1 (en)	2003-06-09	2004-12-16	Boehringer Ingelheim International Gmbh	Inhibitors of papilloma virus
EP1651643A4 (en)	2003-07-31	2008-10-08	Irm Llc	BICYCLIC COMPOUNDS AND COMPOSITIONS USED AS PDF INHIBITORS
FR2875805B1 (fr)	2004-09-27	2006-12-29	Genfit S A	Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
UY30048A1 (es)	2005-12-23	2007-07-31	Astrazeneca Ab	Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
TWI433839B (zh)	2006-08-11	2014-04-11	Neomed Inst	新穎的苯并咪唑衍生物290
EP2139895A1 (en) *	2007-03-23	2010-01-06	F. Hoffmann-Roche AG	Aza-pyridopyrimidinone derivatives
AU2008345225A1 (en) *	2007-12-21	2009-07-09	University Of Rochester	Method for altering the lifespan of eukaryotic organisms
WO2011138265A2 (en)	2010-05-03	2011-11-10	Evotec Ag	Indole and indazole derivatives as orexin receptor antagonists
EP2968240A2 (en) *	2013-03-14	2016-01-20	Janssen Pharmaceutica, N.V.	Physiological ligands for gpr139
JO3719B1 (ar) *	2014-11-20	2021-01-31	Takeda Pharmaceuticals Co	4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

2015
- 2015-11-18 JO JOP/2015/0282A patent/JO3719B1/ar active
- 2015-11-19 PT PT15816275T patent/PT3221298T/pt unknown
- 2015-11-19 ES ES15816275T patent/ES2734735T3/es active Active
- 2015-11-19 EP EP15816275.0A patent/EP3221298B1/en active Active
- 2015-11-19 MD MDE20170117 patent/MD3221298T2/ro unknown
- 2015-11-19 UY UY0001036406A patent/UY36406A/es not_active Application Discontinuation
- 2015-11-19 EP EP19152036.0A patent/EP3536324B1/en active Active
- 2015-11-19 LT LTEP15816275.0T patent/LT3221298T/lt unknown
- 2015-11-19 CN CN202010988947.3A patent/CN112062730B/zh active Active
- 2015-11-19 CA CA2968242A patent/CA2968242C/en active Active
- 2015-11-19 SI SI201530772T patent/SI3221298T1/sl unknown
- 2015-11-19 DK DK15816275.0T patent/DK3221298T3/da active
- 2015-11-19 UA UAA201705041A patent/UA120375C2/uk unknown
- 2015-11-19 DK DK19152036.0T patent/DK3536324T3/da active
- 2015-11-19 GE GEAP201514515A patent/GEP20196961B/en unknown
- 2015-11-19 MA MA40993A patent/MA40993B1/fr unknown
- 2015-11-19 AU AU2015349866A patent/AU2015349866B2/en active Active
- 2015-11-19 SG SG11201704002UA patent/SG11201704002UA/en unknown
- 2015-11-19 TN TN2017000196A patent/TN2017000196A1/en unknown
- 2015-11-19 RS RS20190776A patent/RS59078B1/sr unknown
- 2015-11-19 US US14/946,194 patent/US9556130B2/en active Active
- 2015-11-19 RS RS20211398A patent/RS62563B1/sr unknown
- 2015-11-19 ES ES19152036T patent/ES2897545T3/es active Active
- 2015-11-19 HU HUE19152036A patent/HUE057451T2/hu unknown
- 2015-11-19 KR KR1020177016973A patent/KR102582021B1/ko active Active
- 2015-11-19 MX MX2017006448A patent/MX378158B/es unknown
- 2015-11-19 HR HRP20212009TT patent/HRP20212009T1/hr unknown
- 2015-11-19 CN CN201580071393.8A patent/CN107108531B/zh active Active
- 2015-11-19 WO PCT/US2015/061607 patent/WO2016081736A1/en not_active Ceased
- 2015-11-19 CR CR20170275A patent/CR20170275A/es unknown
- 2015-11-19 MY MYPI2017701778A patent/MY187423A/en unknown
- 2015-11-19 SI SI201531729T patent/SI3536324T1/sl unknown
- 2015-11-19 NZ NZ732208A patent/NZ732208A/en unknown
- 2015-11-19 EA EA201791096A patent/EA033728B1/ru unknown
- 2015-11-19 PL PL19152036T patent/PL3536324T3/pl unknown
- 2015-11-19 PE PE2017000866A patent/PE20170899A1/es unknown
- 2015-11-19 PL PL15816275T patent/PL3221298T3/pl unknown
- 2015-11-19 PT PT191520360T patent/PT3536324T/pt unknown
- 2015-11-19 SM SM20190355T patent/SMT201900355T1/it unknown
- 2015-11-19 JP JP2017526844A patent/JP6637501B2/ja active Active
- 2015-11-19 HU HUE15816275A patent/HUE044145T2/hu unknown
- 2015-11-19 GE GEAP201814515A patent/GEAP201814515A/en unknown
- 2015-11-19 SM SM20220142T patent/SMT202200142T1/it unknown
- 2015-11-19 LT LTEP19152036.0T patent/LT3536324T/lt unknown
- 2015-11-19 HR HRP20191003TT patent/HRP20191003T1/hr unknown
- 2015-11-19 TW TW104138295A patent/TWI684590B/zh active
2016
- 2016-12-16 US US15/382,490 patent/US9770450B2/en active Active
2017
- 2017-05-12 DO DO2017000120A patent/DOP2017000120A/es unknown
- 2017-05-16 IL IL252311A patent/IL252311B/en active IP Right Grant
- 2017-05-18 PH PH12017500920A patent/PH12017500920B1/en unknown
- 2017-05-19 CL CL2017001292A patent/CL2017001292A1/es unknown
- 2017-06-16 CO CONC2017/0005959A patent/CO2017005959A2/es unknown
- 2017-06-20 EC ECIEPI201738999A patent/ECSP17038999A/es unknown
- 2017-08-22 US US15/683,589 patent/US10159677B2/en active Active
2018
- 2018-11-02 US US16/179,709 patent/US10561662B2/en active Active
2019
- 2019-06-20 CY CY20191100646T patent/CY1122613T1/el unknown
- 2019-12-20 JP JP2019229837A patent/JP6918088B2/ja active Active
2020
- 2020-01-02 US US16/732,536 patent/US11173161B2/en active Active
2021
- 2021-12-17 CY CY20211101111T patent/CY1124929T1/el unknown

Also Published As

Publication number	Publication date
ECSP17038999A (es)	2017-10-31
KR20170084324A (ko)	2017-07-19
SMT202200142T1 (it)	2022-05-12
JP2020063285A (ja)	2020-04-23
HRP20212009T1 (hr)	2022-04-01
US20160145218A1 (en)	2016-05-26
US20170348319A1 (en)	2017-12-07
BR112017010311A2 (pt)	2017-12-26
MX2017006448A (es)	2017-09-12
NZ732208A (en)	2023-02-24
CO2017005959A2 (es)	2017-10-20
TW201625566A (zh)	2016-07-16
IL252311B (en)	2020-07-30
CN107108531A (zh)	2017-08-29
AU2015349866B2 (en)	2020-12-03
CA2968242C (en)	2022-11-08
CY1124929T1 (el)	2023-01-05
DK3536324T3 (da)	2021-10-25
CA2968242A1 (en)	2016-05-26
MD3221298T2 (ro)	2019-10-31
TN2017000196A1 (en)	2018-10-19
CL2017001292A1 (es)	2018-02-16
US10159677B2 (en)	2018-12-25
US10561662B2 (en)	2020-02-18
US20190070187A1 (en)	2019-03-07
MX378158B (es)	2025-03-10
RS59078B1 (sr)	2019-09-30
PH12017500920A1 (en)	2017-11-20
PE20170899A1 (es)	2017-07-12
US11173161B2 (en)	2021-11-16
EA033728B1 (ru)	2019-11-20
PL3221298T3 (pl)	2019-10-31
CN112062730B (zh)	2023-09-29
IL252311A0 (en)	2017-07-31
EP3221298B1 (en)	2019-04-03
CN107108531B (zh)	2020-10-20
GEAP201814515A (en)	2018-12-10
LT3221298T (lt)	2019-08-12
PT3536324T (pt)	2021-11-10
ES2734735T3 (es)	2019-12-11
UY36406A (es)	2016-06-30
JO3719B1 (ar)	2021-01-31
HUE044145T2 (hu)	2019-09-30
JP6637501B2 (ja)	2020-01-29
AU2015349866A1 (en)	2017-06-15
MY187423A (en)	2021-09-22
CY1122613T1 (el)	2021-05-05
DOP2017000120A (es)	2017-06-15
KR102582021B1 (ko)	2023-09-22
EP3536324B1 (en)	2021-10-06
HRP20191003T1 (hr)	2019-08-23
PT3221298T (pt)	2019-06-28
MA40993A (fr)	2017-09-27
US9556130B2 (en)	2017-01-31
SI3221298T1 (sl)	2019-10-30
GEP20196961B (en)	2019-03-25
US20170095480A1 (en)	2017-04-06
ES2897545T3 (es)	2022-03-01
HUE057451T2 (hu)	2022-05-28
DK3221298T3 (da)	2019-06-24
JP6918088B2 (ja)	2021-08-11
SMT201900355T1 (it)	2019-07-11
CN112062730A (zh)	2020-12-11
US9770450B2 (en)	2017-09-26
UA120375C2 (uk)	2019-11-25
TWI684590B (zh)	2020-02-11
SG11201704002UA (en)	2017-06-29
EA201791096A1 (ru)	2017-11-30
JP2017535559A (ja)	2017-11-30
PH12017500920B1 (en)	2017-11-20
PL3536324T3 (pl)	2022-02-07
WO2016081736A1 (en)	2016-05-26
US20200129518A1 (en)	2020-04-30
RS62563B1 (sr)	2021-12-31
MA40993B1 (fr)	2019-07-31
SI3536324T1 (sl)	2021-12-31
EP3221298A1 (en)	2017-09-27
EP3536324A1 (en)	2019-09-11
CR20170275A (es)	2017-10-30

Publication	Publication Date	Title
LT3230281T (lt)	2021-07-12	1,3-tiazol-2-ilu pakeisti benzamidai
DK3209778T3 (da)	2019-05-27	Kombination
BR112016030368A2 (pt)	2018-07-17	composição oftálmica
IL252311A0 (en)	2017-07-31	4-oxo-4,3-dihydro-3,2,1-benzotriazines as G protein-coupled receptor modulators 139
DK3466976T3 (da)	2021-12-13	Anti-her2-antistof-lægemiddelkonjugat
BR112016023341A2 (pt)	2017-10-10	composição desinfetante de ação rápida
DK3130649T3 (da)	2025-02-03	Haloolefin-baseret sammensætning
FR3024363B1 (fr)	2018-08-10	Composition thermogelifiable
BR112017001387A2 (pt)	2018-06-05	alargador.
BR112017001386A2 (pt)	2018-06-05	alargador.
FR3023988B3 (fr)	2016-07-22	.
BR112017001389A2 (pt)	2018-06-05	alargador.
BR112017001388A2 (pt)	2018-06-05	alargador.
PT3212237T (pt)	2022-04-14	Formulação de metotrexato
PT3131898T (pt)	2020-06-17	Derivados de fluoroalquilfluoreno
CL2017000639A1 (es)	2018-01-26	Composición
SI3220893T1 (sl)	2023-09-29	Sestavek na osnovi COQ10
HUE070090T2 (hu)	2025-05-28	Összetétel
BR112016027580A2 (pt)	2017-08-15	Formulação de ceritinib
BR112016018071A2 (pt)	2018-05-08	composição de larvicida.
DK3217964T3 (da)	2019-11-25	Sammensætning
FR3019552B1 (fr)	2016-04-01	Composition filmogene
ES1110833Y (es)	2014-08-29	Aparcamiento desmontable.
ES1136182Y (es)	2015-05-08	Senalizador de peldanos fotoluminiscentes
ES1105680Y (es)	2014-07-01	Baliza avifauna.